<DOC>
<DOCNO>EP-0647629</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P4300	C07C24300	C07C25566	C07D40100	A61K31435	C07D23100	A61P114	C07C24322	C07D40104	C07D23114	A61P4300	A61P2500	A61K31415	A61P2500	A61P2518	A61P100	A61K31435	A61P106	C07C25500	A61K31415	A61P100	C07D40114	A61P104	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07C	C07C	C07D	A61K	C07D	A61P	C07C	C07D	C07D	A61P	A61P	A61K	A61P	A61P	A61P	A61K	A61P	C07C	A61K	A61P	C07D	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P43	C07C243	C07C255	C07D401	A61K31	C07D231	A61P1	C07C243	C07D401	C07D231	A61P43	A61P25	A61K31	A61P25	A61P25	A61P1	A61K31	A61P1	C07C255	A61K31	A61P1	C07D401	A61P1	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The subject of the invention is substituted 1-naphthylpyrazole-3-carboxamides of formula I: 
<
IMAGE
>
   Application: treatment of neuropsychiatric disorders, in particular those which are associated with dysfunctioning of the dopaminergic systems.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
A compound of formula:


   in which :

R represents a group selected from :

-CN, -C(NH
2
) N-OH, -C(NR
4
R
5
) = NR
6
,

-CONR
1
R
2
, CON(R
7
)(CH
2
)
p
NR
1
R
2
,

-CON(R
7
)(CH
2
)
q
CN, -CON(R
7
)(CH
2
)
q
C(NR
14
R
15
) = N-R
16
,

-CH
2
CN, -CH
2
CONR
1
R
2
, -CH
2
CON(R
7
)(CH
2
)
p
NR
1
R
2
,

CH
2
CON(R
7
)(CH
2
)
q
CN, -CH
2
COOR
7,

O(CH
2
)
n
NR
1
R
2
, -O(CH
2
)
n
CONR
1
R
2
,

-O(CH
2
)
n
COOR
7
, -O(CH
2
)
n
SO
2
NR
1
R
2
,

-N(R7)COR
3
, -N(R
7
)CO(CH
2
)
n
NR
1
R
2
,

-N(R
7
)CO(CH
2
)
n
NHCOR
3
, -N(R
7
)SO
2
R
8
,
 
-N(R
7
)CONR
9
R
10
, -CH
2
N(R
7
)COR
3
,

-CH
2
N(R
7
)SO
2
R
8
, -CH
2
CH
2
NR
11
R
12
,

-CH
2
CH
2
N(R
7
)COR
3
, -CH
2
CH
2
N(R
7
)SO
2
R
8
,

-SO
2
NR
1
R
2
, -SO
2
N(R
7
)(CH
2
)
n
NR
1
R
2
,

-CH
2
CON(R
7
)(CH
2
)
q
C(NR
14
R
15
)= NR
16

-N(R
7
)CO(CH
2
)
q
CN, -N(R
7
)CO(CH
2
)
q
C(NR
14
R
15
) = NR
16
,

SO
2
N(R
7
)(CH
2
)
q
CN SO
2
N(R
7
)(CH
2
)
q
C(NR
14
R
15
) = NR
16
 ;
or even R, bound to the carbon atom in position 5 of the naphthyl
radical, forms a -CON(R
13
)CO- group
p = 2 to 6 ;
n = 1 to 6 ;
q = 1 to 5 ;
R
1
 and R
2
 each independently represent a hydrogen or a
(C
1
-C
4
)alkyl ; or R
1
 and R
2
 together with the nitrogen atom to which
they are bound represent a heterocycle selected from : pyrrolidine,

piperidine, piperazine substituted in position -4- with R
7
, morpholine,
or thiomorpholine;
R
3
 represents hydrogen ; a (C
1
-C
8
)alkyl ; a (C
3
-C
8
)cycloalkyl ; a
phenyl ; or a piperidyl ;
R
4
 and R
5
 each independently represent a hydrogen or a
(C
1
-C
4
)alkyl ;
R
6
 represents a (C
1
-C
4
)alkyl ; 
R
7
 represents a hydrogen or a (C
1
-C
4
)alkyl ;
R
8
 represents a (C
1
-C
4
)alkyl ;
R
9
 and R
10
 each independently represent a hydrogen or a
(C
1
-C
4
)alkyl ; R
10
 can also represent a -(CH
2
)
n
NR
1
R
2
 group ;
or R
9
 and R
10
 together with the nitrogen atom to which they are
bound represent a heterocycle selected from : pyrrolidine, piperidine,

piperazine substituted in position 4 with R
7
, morpholine or
thiomorpholine :
R
11
 and R
12
 each independently represent a hydrogen or a
(C
1
-C
4
)alkyl ; or R
11
 and R
12
 together with the nitrogen atom to
which they are bound represent pyrrolidine or piperidine ;
R
13
 represents a hydrogen ; a -(CH
2
)
n
NR
1
R
2
 group ; or an
-NHCOR
3
 group ;
R
14
 and R
15
 each independently represent a hydrogen or a
(C
1
-C
4
)alkyl ;
R
16
 represents a hydrogen ; R
16
 can also represent a (C
1
-C
4
)alkyl
when R
14
 represents a hydrogen and R
15
 represents a (C
1
-C
4
)alkyl ;
or R
14
 and R
16
 together represent an ethylene group or a trimethylene
group, and R
15
 represents a hydrogen or a (C
1
-C
4
)alkyl ;
T represents hydrogen ; a (C
1
-C
4
)alkyl ; an allyl ; a (C
3
-C
8
)cycloalkyl ; a
(C
3
-C
8
)cycloalkylmethyl ; or methoxyethyl ;
the -NH-AA(OH) group represents the amino acid residue :


wherein X is hydrogen and X' is hydrogen, a (C
1
-C
5
)alkyl or a nonaromatic
C
3
-C
15
 carbocyclic radical ; or even X and X', together with
the carbon atom to which they are bound, form a non-aromatic C
3
-C
15

carbocycle; and its salts.
The compound according to claim 1 of formula 1 in which : 

R represents an aminocarbonyl ; aminocarbonylmethyl ; acetamido ;
N-(3-N',N'-dimethylaminopropyl)aminosulphonyl ; N-methyl-N-(3-N',N'-dimethylaminopropyl)aminosulphonyl

; carbamoylmethyloxy ; N-(3-N',N'-dimethylaminopropyl)aminocarbonyl
; N-(2-N',N'-dimethylaminoethyl)aminocarbonyl

; N-methyl-N-(3-N',N'-dimethylaminopropyl)aminocarbonyl;
N-methyl-N-(2-N',N'dimethylaminoethyl)aminocarbonyl

; or N-methyl-N-[2-N
1
-methyl-N
2
-methylamidino)ethyl]carbamoyl

group ;
T represents a methyl or cyclopropylmethyl group ; and
the -NH-AA-(OH) group represents a 2-aminoadamantane-2-carboxylic
or (S)α-aminocyclohexaneacetic acid residue ; and its salts.
The compound according to claim 1, of formula :


   in which

R
a
 represents an N-(3-N',N'-dimethylaminopropyl)aminocarbonyl or
N-(2-N',N'-dimethylaminoethyl)aminocarbonyl group ;

and its salts.
A method for the preparation of a compound according to claim 1 of
formula I and of its salts, characterised in that :


1) a functional derivative of a 1-naphthylpyrazole-3-carboxylic acid of
formula: 



   in which T and R have the meanings given above for the compound of
formula I and R' represents a precursor of R selected from nitro, amino,

hydroxy, sulpho, chlorosulphonyl, and carboxy groups, is treated with
an amino acid, optionally protected with protecting groups usual in

peptide synthesis, of formula :

H-HN-AA(OH)

in which -NH-AA(OH) is as defined above for the compound of
formula I ;
2) if necessary, the resulting compound of formula :


   is subjected to a further treatment which is suitable for converting the R
1

substituent, precursor of R, into the R substituent ;
3) optionally, the compound thus obtained in step 1) or in step 2) is
deprotected to lead to the corresponding free acid of formula I ;
4) if necessary, a salt of compound I thus obtained is prepared.
An acid of formula :


   in which T and R have the definitions given in claims 1 for compounds I
and R' represents a precursor of R selected from nitro, amino, hydroxy,

sulpho, and chlorosulphonyl groups, as well as chloride or C
1
-C
4
 alkyl
ester of said acid, or mixed anhydride of said acid with ethyl or isobutyl

chloroformate.
A compound of formula :


   in which :

R
y
 represents a cyano or carboxymethyl group ; and its salts.
A pharmaceutical composition containing as active principle a
compound of formula I according to any one of claims 1 to 3, or one of

its optional pharmaceutically acceptable salts.
The pharmaceutical composition according to claims 7 in the form of a
unit dose. 
The pharmaceutical composition according to claim 8, characterised in
that it contains 0.5 to 250 mg of active principle in a mixture with at

least one pharmaceutical excipient.
</CLAIMS>
</TEXT>
</DOC>
